Thalidomide 4'-ether-alkylC2-amine is primarily used in research and pharmaceutical development due to its structural modifications, which enhance its biological activity and selectivity. It is being studied for its potential application in cancer therapy, particularly in targeting specific pathways involved in tumor growth and angiogenesis. The compound’s ability to modulate immune responses makes it a candidate for treating autoimmune diseases and inflammatory conditions. Additionally, its modified structure allows for improved pharmacokinetics, making it a promising agent in drug delivery systems. Researchers are also exploring its role in combination therapies to enhance the efficacy of existing treatments while minimizing side effects.